Emcitate (tiratricol) is an oral thyroid hormone analog approved for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome.
MCT8 deficiency is a rare genetic disorder caused by mutations affecting monocarboxylate transporter 8, which plays an important role in transporting thyroid hormones into cells. Tiratricol can enter cells without relying on the defective transporter and helps reduce elevated thyroid hormone levels in the bloodstream.
Emcitate is the first FDA-approved therapy for MCT8 deficiency and addresses a significant unmet medical need in this rare genetic disorder. By reducing excess circulating thyroid hormone levels, the therapy is designed to manage peripheral thyrotoxicosis and its associated systemic effects. Its targeted mechanism provides a new therapeutic approach for patients with MCT8 deficiency and expands treatment options for this rare endocrine disorder.
